Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
The newly developed antibody 6H4 fragments (Fabs) specific to Aβ oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-AβO 6H4 Fabs in the PMs, various toxic Aβ species (Aβ oligomers, Aβ42s, N3pE Aβs, Aβs with toxic conformer) and the presence of Aβ plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by…
